Article Information
History
- August 21, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Niveditha Ravindra1,
- Laura W. Dillon1,
- Gege Gui1,
- Matthew Smith2,
- Lukasz P. Gondek2,
- Richard J. Jones2,
- Adam Corner3,
- Christopher S. Hourigan1,4,*,† and
- Alexander J. Ambinder2,*
- 1Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
- 2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
- 3Bio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA
- 4Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD
- ↵†Corresponding Author:
Christopher S. Hourigan DM DPhil FRCP, Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20814-1476, Email: hourigan{at}nih.gov
↵* CSH and AJA contributed equally to this work
Posted August 21, 2023.
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
